In addition to Smolensk, PPD has added offices in Moscow and St Petersburg, Russia, and Kiev, Ukraine, with this acquisition.
Sergey Sudilovsky, currently director general of InnoPharm, will oversee operations in Russia and Ukraine for PPD. Dr Sudilovsky has more than 15 years of experience with InnoPharm, having spent the past 10 years as director general.
Fred Eshelman, CEO of PPD, said: “The number of clinical trials approved in Russia has nearly doubled over the past six years as the country continues to emerge as a high-growth market for clinical research. Acquiring InnoPharm strengthens our presence in Russia and Ukraine and will serve as the foundation for continued growth in a region we have targeted for expansion.”